Jupiter Neurosciences agrees to pay $3.33 million for exclusive US rights to PharmAla’s ALA-002

Jupiter Neurosciences, Inc.

Jupiter Neurosciences, Inc.

JUNS

0.00
  • Jupiter Neurosciences entered a term sheet to acquire exclusive, perpetual U.S. licensing rights to PharmAla Biotech’s ALA-002, a next-generation MDMA drug candidate.
  • The deal values the upfront consideration at USD 3.33 million, split between USD 1.5 million in cash and USD 1.83 million in common stock, with additional development milestones and single-digit royalties.
  • ALA-002 is a patented, non-racemic MDMA formulation that the FDA has recognized as a Novel Chemical Entity, with the companies citing improved cardiovascular safety and reduced abuse liability versus racemic MDMA.
  • Jupiter agreed to place USD 600,000 into escrow on signing, credited against the upfront cash payment at closing.
  • The parties target signing definitive agreements within 90 days, subject to due diligence and customary approvals.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jupiter Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605200738PRIMZONEFULLFEED9723854) on May 20, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.